Response of brain metastasis from lung cancer patients to an oral nutraceutical product containing silibinin
Joaquim Bosch‐Barrera(Universitat de Girona), Javier A. Menéndez(Institut Català d'Oncologia), Salvador Pedraza(Hospital Clínic de Barcelona), Manel Haro(Universitat de Girona), Noemí Cañete(Institut d'Investigació Biomèdica de Girona), Joan Brunet(Institut Català d'Ornitologia), J. Marruecos(Institut Català d'Oncologia), Elisabet Cuyàs(Institut Català d'Oncologia), Á. Izquierdo(Catalan Institute for Water Research), Rut Porta(Catalan Institute for Water Research), Èlia Sais(Institut Català d'Oncologia)
Cited by 52
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
|New England Journal of Medicine|2009|2.4k
MRI-Guided Thrombolysis for Stroke with Unknown Time of Onset
|New England Journal of Medicine|2018|1.3k
Perfusion-CT Assessment of Infarct Core and Penumbra
|Stroke|2006|771
Comparative Overview of Brain Perfusion Imaging Techniques
|Stroke|2005|586